8 completed, 2 terminated. 5 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 5 | Completed 3, Terminated 2 |
Follow ruzasvir: new trials by email Literature Review of ruzasvir trials Research Report on ruzasvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG) Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG) - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 24 | 2025-12-04 | 2026-04-13 |
| Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fasting conditions, Bemnifosbuvir (BEM)/Ruzasvir (RZR) FDC under fed conditions, Bemnifosbuvir (BEM) and Ruzasvir (RZR) as reference formulation under fasting conditions - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 42 | 2023-12-14 | 2024-09-19 |
| A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic | Phase 2 | Completed | Atea Pharmaceuticals, Inc. | 275 | 2023-05-30 | 2025-10-21 |
| Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir Cohort 1 BEM + Ruzasvir, Cohort 2 Ruzasvir + BEM - Healthy Volunteer Study | Phase 1 | Completed | Atea Pharmaceuticals, Inc. | 32 | 2023-01-30 | 2023-06-01 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041) Uprifosbuvir, Ruzasvir, Ribavirin - Hepatitis C | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 282 | 2016-11-16 | 2021-02-02 |
| Efficacy and Safety of Uprifosbuvir (MK-3682) With Ruzasvir (MK-8408) in Adults With Chronic Hepatitis C Genotype 1, 2, 3, 4, 5 or 6 Infection (MK-3682-035) Uprifosbuvir 450 mg, Ruzasvir 60 mg - Hepatitis C, Chronic | Phase 2 | Terminated | Merck Sharp & Dohme LLC | 160 | 2016-05-03 | 2019-06-26 |
| A Study of the Pharmacokinetics of Uprifosbuvir (MK-3682) and Ruzasvir (MK-8408) in Participants With Moderate and Severe Hepatic Insufficiency (MK-3682-029) Uprifosbuvir, Ruzasvir - Hepatitis C, Chronic | Phase 1 | Completed | Merck Sharp & Dohme LLC | 24 | 2016-01-22 | 2018-09-17 |
| Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Virus (HCV) Genotype (GT) 3, GT4, GT5, and GT6 Infection (MK-3682-012) Grazoprevir, Uprifosbuvir, Elbasvir - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 413 | 2015-01-28 | 2019-07-30 |
| Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011) Grazoprevir, Uprifosbuvir, Elbasvir - Hepatitis C | Phase 2 | Completed | Merck Sharp & Dohme LLC | 443 | 2015-01-22 | 2019-07-23 |
| Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003) Ruzasvir - Hepatitis C Infection | Phase 1 | Completed | Merck Sharp & Dohme LLC | 22 | 2014-03-27 | 2018-12-24 |
Hepatitis C (5) · Hepatitis C, Chronic (3) · Liver Cirrhosis (1)
Merck Sharp & Dohme LLC (6) · Atea Pharmaceuticals, Inc. (4)
Canada (3) · United States (2) · Brazil (1) · India (1) · Mauritius (1) · Moldova (1) · Pakistan (1) · Philippines (1) · Romania (1) · South Africa (1) · South Korea (1) · Turkey (Türkiye) (1)
PMID 28802814, PMID 28802816, PMID 31108015, PMID 30739366
2014 (2), 2016 (1)